0001062993-22-022854.txt : 20221128
0001062993-22-022854.hdr.sgml : 20221128
20221128182830
ACCESSION NUMBER: 0001062993-22-022854
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221123
FILED AS OF DATE: 20221128
DATE AS OF CHANGE: 20221128
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rottinghaus Scott T.
CENTRAL INDEX KEY: 0001942407
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35839
FILM NUMBER: 221427624
MAIL ADDRESS:
STREET 1: C/O ENANTA PHARMACEUTICALS, INC.
STREET 2: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001177648
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617 607 0800
MAIL ADDRESS:
STREET 1: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2022-11-23
0001177648
ENANTA PHARMACEUTICALS INC
ENTA
0001942407
Rottinghaus Scott T.
C/O ENANTA PHARMACEUTICALS, INC.
500 ARSENAL STREET
WATERTOWN
MA
02472
0
1
0
0
Chief Medical Officer
Common Stock
2022-11-23
4
A
0
7000
0.00
A
27000
D
Stock Option (right to buy)
45.00
2022-11-23
4
A
0
15000
0.00
A
2032-11-23
Common Stock
15000
15000
D
Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs will vest and settle with respect to 25% of the award on December 4, 2023 and in substantially equal annual installments over the next three anniversaries thereafter.
Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 23, 2022).
/s/ Nathaniel S. Gardiner as attorney-in-fact
2022-11-28